**Kalaris Therapeutics, Inc. Reports Annual Financial Results and Provides Business Update**
Kalaris Therapeutics, Inc. (formerly AlloVir, Inc.), a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases, released its financial results for the year ended December 31, 2025. The company reported a net loss of $43.4 million, compared to a net loss of $69.2 million for the year ended December 31, 2024. This decrease in net loss was primarily driven by a reduction in research and development expenses and a gain from changes in the fair value of tranche and derivative liabilities, partially offset by increased general and administrative costs. As the company has no approved products, it did not generate any revenue from product sales during either period.
The company's research and development expenses totaled $30.8 million in 2025, a decrease from $45.0 million in 2024. This decrease was mainly due to a one-time royalty obligation expense of $32.1 million incurred in 2024 related to an agreement with Samsara BioCapital L.P. This decrease was partially offset by increased spending on CDMO, CRO, and consulting costs related to the ongoing Phase 1a and Phase 1b/2 clinical trials of TH103, as well as increased personnel-related costs. General and administrative expenses increased to $15.4 million in 2025 from $6.7 million in 2024, primarily due to higher legal, accounting, and professional service fees, increased directors' and officers' insurance costs, and increased personnel-related expenses associated with operating as a public company.
Operationally, Kalaris Therapeutics continued to advance its lead product candidate, TH103, a novel anti-VEGF drug for retinal diseases. The company is currently conducting a Phase 1b/2 multiple ascending dose study to assess the safety and efficacy of TH103 in patients with neovascular age-related macular degeneration (nAMD). Preliminary data from this study is expected in the first half of 2027. The company also plans to expand the development of TH103 into other VEGF-mediated retinal diseases, such as diabetic eye disease and retinal vein occlusion. As of the date of the filing, the company had dosed a total of 17 patients in its ongoing Phase 1b/2 MAD trial.
Looking ahead, Kalaris Therapeutics anticipates that its existing cash, cash equivalents, and short-term marketable securities of $118.0 million as of December 31, 2025, will be sufficient to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2027. The company expects to continue to incur significant expenses as it progresses TH103 through clinical development and expands its research and development activities. The company also intends to opportunistically complement its ongoing development programs by accessing additional product candidates and technologies through internal discovery and development, in-licensing, strategic collaborations and/or acquisitions.
About Kalaris Therapeutics, Inc.
AlloVir, Inc. is a biopharmaceutical company specializing in allogeneic, off-the-shelf virus-specific T cell (VST) therapies designed to restore immunity in immunocompromised patients at risk of life-threatening viral infections. Its proprietary platform develops multi-virus and single-virus targeted cell therapies for transplant recipients and patients with viral diseases. The company’s business model focuses on developing, manufacturing, and commercializing VST therapies through patented technology and strategic collaborations.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.